Louis Dubeau, MD, PhD

Professor of Pathology

Image of Louis Dubeau, MD, PhD
Is this your profile? Click to edit

Overview

For many years, Dr. Dubeau has been a leading practitioner, educator and researcher in the field of ovarian cancer biology. A native of Canada, Dr. Dubeau first came to USC as a post-doctoral fellow at the Norris Comprehensive Cancer Center. During his time at USC, Dr. Dubeau has achieved the status of full professor, become director of the Molecular Diagnostics Laboratory at USC/Norris Comprehensive Cancer Center published numerous peer-reviewed articles for medical journals and lectured at medical conferences and seminars across the United States, Canada, United Kingdom, Hungary, Turkey and Greece. Dr. Dubeau is a renowned researcher and has been awarded over fourteen million dollars in research grants, many dealing with either ovarian cancer biology and genetics or with environmental issues such as exposure to and effects of air pollution. A devoted educator, Dr. Dubeau has mentored over fifty students, either as a member of their PhD advisory committee or by training doctoral and graduate students. Dr. Dubeau also has found time throughout his career to give lectures on health related subjects to area public school students.

Research Funding

  • Role of the Mullerian Tract in Ovarian Cancer Development
    NIH · R01CA133117 · May 1, 2009 – Feb 28, 2015 · Role: Principal Investigator
  • CELL NON-AUTONOMOUS MODE OF TUMOR SUPPRESSION BY BRCA1
    NIH · R01CA119078 · Aug 1, 2006 – Jul 31, 2011 · Role: Principal Investigator
  • TELOMERASE ASSAY FOR OVARIAN CANCER DETECTION
    NIH · R01CA079750 · Mar 7, 2000 – Feb 28, 2006 · Role: Principal Investigator
  • HISTOGENESIS AND EARLY DEVELOPMENT OF OVARIAN CARCINOMA
    NIH · R55CA060743 · Sep 30, 1993 – Sep 29, 1996 · Role: Principal Investigator
  • SEQUENTIAL GENETIC CHANGES DURING TUMOR DEVELOPMENT
    NIH · R01CA051167 · Jul 1, 1990 – Jun 30, 2000 · Role: Principal Investigator
  • SEQUENTIAL GENETIC CHANGES DURING TUMOR DEVELOPMENT
    NIH · R29CA051167 · Jul 1, 1990 – Jun 30, 1995 · Role: Principal Investigator

Publications

  • Methionine-supplemented longevity diet increases growth hormone, GLP-1, and FGF21; reduces frailty; and promotes healthspan. Cell Metab. 2026 Jun 23.. View in PubMed
  • The cervico-vaginal DNA methylation WID-qEC test: An epigenetic marker associated with ovarian cancer in the absence of endometrial and cervical cancer. Int J Cancer. 2026 May 15; 158(10):2530-2536.. View in PubMed
  • Personalized Primary and Secondary Prevention in Ovarian Cancer. JAMA Oncol. 2025 Oct 01; 11(10):1132-1133.. View in PubMed
  • Natural Killer Cell Dysfunction in Premenopausal BRCA1 Mutation Carriers: A Potential Mechanism for Ovarian Carcinogenesis. Cancers (Basel). 2024 Mar 18; 16(6).. View in PubMed
  • Neurotropism of SARS-CoV-2: A Pathological Examination of Neurosurgical Specimens. Neurosurgery. 2024 02 01; 94(2):379-388.. View in PubMed
  • Embryological Insights into the Origin of Epithelial Cancers of the Female Reproductive Tract. Cold Spring Harb Perspect Med. 2023 07 05; 13(7).. View in PubMed
  • GRP78 Inhibitor YUM70 Suppresses SARS-CoV-2 Viral Entry, Spike Protein Production and Ameliorates Lung Damage. Viruses. 2023 05 06; 15(5).. View in PubMed
  • Correction: Antiprogestins reduce epigenetic field cancerization in breast tissue of young healthy women. Genome Med. 2022 Jul 19; 14(1):76.. View in PubMed
  • Antiprogestins reduce epigenetic field cancerization in breast tissue of young healthy women. Genome Med. 2022 06 15; 14(1):64.. View in PubMed
  • Endoplasmic reticulum chaperone GRP78/BiP is critical for mutant Kras-driven lung tumorigenesis. Oncogene. 2021 05; 40(20):3624-3632.. View in PubMed